Jason Bednar

Stock Analyst at Piper Sandler

(2.30)
# 2,668
Out of 5,147 analysts
201
Total ratings
42.67%
Success rate
-2%
Average return

Stocks Rated by Jason Bednar

ICU Medical
Feb 20, 2026
Maintains: Overweight
Price Target: $172$178
Current: $150.58
Upside: +18.21%
Merit Medical Systems
Feb 18, 2026
Maintains: Overweight
Price Target: $113$106
Current: $77.18
Upside: +37.34%
Becton, Dickinson and Company
Feb 10, 2026
Reiterates: Neutral
Price Target: $205$170
Current: $176.48
Upside: -3.67%
Envista Holdings
Feb 6, 2026
Reiterates: Neutral
Price Target: $21$25
Current: $29.21
Upside: -14.41%
Align Technology
Feb 5, 2026
Maintains: Overweight
Price Target: $200$220
Current: $190.10
Upside: +15.73%
GE HealthCare Technologies
Jan 30, 2026
Maintains: Overweight
Price Target: $91$94
Current: $84.27
Upside: +11.55%
Medline
Jan 12, 2026
Initiates: Overweight
Price Target: $50
Current: $47.51
Upside: +5.24%
Sotera Health Company
Jan 9, 2026
Upgrades: Overweight
Price Target: $17$24
Current: $16.25
Upside: +47.69%
The Cooper Companies
Dec 5, 2025
Reiterates: Overweight
Price Target: $83$94
Current: $83.67
Upside: +12.35%
Solventum
Nov 7, 2025
Maintains: Overweight
Price Target: $94$98
Current: $74.20
Upside: +32.08%
Maintains: Neutral
Price Target: $3.5$4
Current: $4.77
Upside: -16.14%
Maintains: Overweight
Price Target: $200$210
Current: $175.35
Upside: +19.76%
Downgrades: Neutral
Price Target: $9$2.5
Current: $1.58
Upside: +58.23%
Reiterates: Overweight
Price Target: $34
Current: $13.67
Upside: +148.72%
Maintains: Neutral
Price Target: $20$16
Current: $14.68
Upside: +8.99%
Maintains: Overweight
Price Target: $83$77
Current: $82.39
Upside: -6.54%
Maintains: Overweight
Price Target: $5$4.5
Current: $4.37
Upside: +2.97%
Maintains: Overweight
Price Target: $260$265
Current: $252.35
Upside: +5.01%
Maintains: Overweight
Price Target: $8$6
Current: $3.40
Upside: +76.47%
Reiterates: Overweight
Price Target: $7
Current: $7.76
Upside: -9.79%
Maintains: Overweight
Price Target: $70$20
Current: $0.96
Upside: +1,980.95%
Maintains: Outperform
Price Target: $310$372
Current: $503.51
Upside: -26.12%